NASDAQ$CRBU
Caribou Biosciences Inc · Q1 2022 earnings
Q1 2022 earnings · · Investor relations
Briefing
Caribou Biosciences reported financial results for the first quarter of 2022 and provided business updates.
Caribou Biosciences reported a net loss of $19.1 million for the first quarter of 2022, compared to a net loss of $13.2 million for the same period in 2021. The company's cash, cash equivalents, and marketable securities totaled $390.8 million as of March 31, 2022.
- Initial ANTLER Phase 1 clinical data is scheduled to be shared at the European Hematology Association (EHA) 2022 Hybrid Congress for CB-010 in patients with r/r B-NHL.
- Submission of IND application planned in H2 2022 for CB-011 for evaluation in patients with r/r multiple myeloma.
- Caribou had $390.8 million in cash, cash equivalents, and marketable securities as of March 31, 2022.
- Caribou expects to announce target selection for CB-020 in Q4 2022.
Headline financials
Revenue & EPS history
Caribou Biosciences · Revenue · Quarterly
$2.66M
Revenue by segment
Caribou Biosciences · $2.66M total across 1 segment · Q1 2022
- Licensing & collaboration$2.66M+68.0%100.0%
Forward guidance
Caribou anticipates several milestones for 2022 and beyond, focusing on clinical data releases, IND application submissions, and target selection announcements for their allogeneic CAR-T and CAR-NK cell therapies.
Tailwinds
- CB-010: Scheduled to share initial data from its ongoing ANTLER Phase 1 trial at EHA in June 2022.
- CB-011: Expects to submit an IND application in H2 2022.
- CB-020: Expects to announce target selection in Q4 2022.
- CB-012: Expects to submit an IND application in 2023.
- Presents poster highlighting the mechanism underlying the superior specificity of its CRISPR hybrid RNA-DNA (chRDNA) guides for genome editing of primary human T cells on May 16, 2022
Headwinds
- Risks inherent in the development of cell therapy products.
- Uncertainties related to the initiation, cost, timing, progress, and results of current and future research and development programs, preclinical studies, and clinical trials.
- Risk that initial or interim clinical trial data will not be predictive of the safety and efficacy of Caribou’s product candidates.
- Clinical outcomes may differ as more patient data becomes available.
- Reliance on forward-looking statements as predictions of future events.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q1 2022
-0.8%
Avg return
Earnings day
+0.9%
Avg return
5 days after
-5.2%
Avg return
30 days after
53%
10 / 19 earnings
Positive
+11.1%
Q2 2021
Best reaction
-32.3%
Q4 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -4.1% | +4.1% | -1.5% | |
| Q4 2025 | +6.5% | +15.2% | +13.5% | |
| Q3 2025 | -12.1% | -17.3% | -20.8% | |
| Q1 2025 | +10.5% | +16.7% | +19.4% | |
| Q4 2024 | +0.1% | -8.6% | -22.2% | |
| Q3 2024 | +8.6% | +9.0% | -16.8% | |
| Q2 2024 | -3.1% | -0.8% | -6.4% | |
| Q1 2024 | -8.6% | -7.6% | -45.4% | |
| Q4 2023 | -32.3% | -27.6% | -41.4% | |
| Q3 2023 | -5.0% | -19.3% | +24.7% | |
| Q2 2023 | +5.2% | +5.8% | -12.0% | |
| Q1 2023 | +9.3% | -2.1% | +4.0% | |
| Q4 2022 | -11.8% | -11.4% | -9.9% | |
| Q3 2022 | +3.9% | +15.0% | +2.4% | |
| Q2 2022 | +10.1% | +17.3% | +40.7% | |
| Q1 2022 | -0.5% | +22.4% | +23.7% | |
| Q4 2021 | +2.6% | -5.6% | -16.1% | |
| Q3 2021 | -4.9% | -0.5% | -18.2% | |
| Q2 2021 | +11.1% | +12.3% | -17.3% | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro